AI MARKET SCANNING

Celcuity Inc.

📅 Next Catalyst: Nov 18, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.87%
MAX GAP RECORD +13.00%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CELC
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 18, 2026 Earnings Release 2026-11-18 (AFTER CLOSE) 🔮 UPCOMING 🔒
Aug 13, 2026 Earnings Release 2026-08-13 (AFTER CLOSE)
-4.11%
May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE)
+0.83%
Mar 25, 2026 Earnings Release 2026-03-25 (AFTER CLOSE)
-0.88%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
+0.00%
Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE)
+1.98%
May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE)
+0.00%
Nov 14, 2024 Earnings Release 2024-11-14 (AFTER CLOSE)
-0.28%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.3%
Bullish Gaps (5)
Bearish Gaps (3)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CELC

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes,…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗